{
    "nctId": "NCT00075673",
    "briefTitle": "Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer",
    "officialTitle": "A Phase I Study of Weekly Administration of Oral Navelbine in Combination With the COX-2 Inhibitor Celebrex in Relapsed and/or Metastatic Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 6,
    "primaryOutcomeMeasure": "Determine the maximum tolerated dose of vinorelbine and celecoxib in women with relapsed or metastatic breast cancer.",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed adenocarcinoma of the breast\n\n  * Recurrent or metastatic (stage IV) disease\n  * Incurable disease\n* Measurable or evaluable disease\n* Stable brain metastases allowed\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* ECOG 0-1\n\nLife expectancy\n\n* More than 3 months\n\nHematopoietic\n\n* Absolute neutrophil count \u2265 1,500/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n* Hemoglobin \u2265 8.0 g/dL\n\nHepatic\n\n* Bilirubin normal\n* AST/ALT \u2264 2.5 times upper limit of normal\n\nRenal\n\n* Creatinine normal OR\n* Creatinine clearance \u2265 60 mL/min\n* No clinically significant proteinuria\n* No impaired renal function\n\nCardiovascular\n\n* No symptomatic congestive heart failure\n* No unstable angina\n* No cardiac arrhythmia\n* No inadequately controlled hypertension\n\nGastrointestinal\n\n* No disorder that would alter gastrointestinal motility or absorption\n* No dysphagia\n* Able to swallow tablets or capsules\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No hypersensitivity to celecoxib\n\n  * No prior urticaria, asthma, or other allergic-type reaction after taking aspirin or other nonsteroidal anti-inflammatory drugs\n* No allergy to sulfa\n* No other concurrent uncontrolled illness\n* No psychiatric illness or social situation that would preclude study compliance\n* No ongoing or active infection\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* At least 3 weeks since prior trastuzumab (Herceptin\u00ae) and recovered\n* No concurrent hematopoietic growth factors\n\nChemotherapy\n\n* At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered\n* Prior adjuvant or neoadjuvant chemotherapy allowed\n* Prior chemotherapy for recurrent or metastatic disease allowed\n* No prior vinorelbine\n\nEndocrine therapy\n\n* At least 2 weeks since prior hormonal therapy\n* Prior adjuvant or neoadjuvant hormonal therapy allowed\n* Prior hormonal therapy for recurrent or metastatic disease allowed\n\nRadiotherapy\n\n* At least 4 weeks since prior radiotherapy for metastatic disease\n* Prior adjuvant radiotherapy allowed\n\nSurgery\n\n* Not specified\n\nOther\n\n* At least 3 weeks since prior investigational anticancer agents and recovered\n* At least 1 week since prior cyclooxygenase-2 (COX-2) inhibitors, except celecoxib\n* No concurrent administration of any of the following drugs:\n\n  * Lithium\n  * Fluconazole\n  * Aluminum antacids\n  * Magnesium antacids\n* Concurrent H_2 blocking agents or proton pump inhibitors allowed for the treatment of dyspepsia or gastroesophageal reflux disease\n* Concurrent bisphosphonates allowed",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}